Top Big Cap Negative News Movers Premarket:  Gold and Silver names weak  ALMS: -54% Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) RZLV: -10% Earnings 01-SEP-2026 09:27 AM ET